USA Equities Corp (USAQ) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of USA Equities Corp $0.53, price $0.32, upside +64.7%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch USA Equities Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0160 – $0.9200 · fair‑value band $0.2890 – $0.9180 · the $0.3200 price screens below the $0.5270 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow USA Equities in your weekly email
Every Wednesday you see whether USA Equities is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
QHSLab, Inc., a medical device technology and software-as-a-service (SaaS) company, provides tools to evaluate and treat chronic disease and preventive care through reimbursable procedures.
Show more
QHSLab, Inc., a medical device technology and software-as-a-service (SaaS) company, provides tools to evaluate and treat chronic disease and preventive care through reimbursable procedures. The company focuses on value-based healthcare, informatics, and algorithmic personalized medicine, including digital therapeutics, behavior based remote patient monitoring, and chronic care and preventive medicine. Its digital healthcare and clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, address chronic care, and preventive medicine. The company provides quality health system lab expert system (QHSLab), designed to function as an extension of a medical practice's existing clinical workflow that supports structured screening, automated documentation, and digital follow-up while minimizing disruption to physicians and staff; and AllergiEnd, a diagnostic and allergen immunotherapy system for the busy non-allergist in a primary care setting. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. The company was incorporated in 1983 and is based in West Palm Beach, Florida.
Stock analysis
USA Equities Corp (USAQ) currently trades at $0.3200, while our model-based Fair Value estimate is $0.5270, implying the stock looks roughly 39.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $1.41 per share, and 15 of the 23 models we run sit above the $0.3200 price.
Bear case: the Asset-Based group reads lowest at $0.0700, and 8 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.2890 (bear) to $0.9180 (bull), the price of $0.3200 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
USA Equities Corp reported revenue of $2.7M in FY2025 versus $1.4M in FY2021, a compound +17.5%/yr. Reported net income was $457K in FY2025.
Key figures
Market cap $4.8M · P/E ratio 10.7 · P/S ratio 1.81 · EPS (TTM) $0.0300 · Net margin 17.0% · Return on equity 93.2% · Return on assets (EBIT) −9.6% · Operating margin −13.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 65% below its 52-week high and 300% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 65%, USAQ screens cheaper than that median.
Fair Value models
Bear $0.2890Fair Value $0.5270Bull $0.9180
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0219 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+26.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+84.9%
Start year 2020 (pandemic)
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
’00
’01
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−220.9% (2020) → 4.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +9.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+65% · Top 25%
Profitability
Return on equity (TTM)93% · Top 25%
Return on assets2% · Above median
Net margin (TTM)16% · Top 25%
Operating margin (TTM)−13% · Below median
Growth and dividend
Revenue growth13% · Above median
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is USA Equities Corp (USAQ) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.5270 versus a price of $0.3200, about +65% upside (undervalued).
What is the fair value of USAQ?
Our model-based fair value for USA Equities Corp is $0.5270 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.3200.
What is the quality score of USAQ?
USA Equities Corp has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for USA Equities Corp (USAQ)?
Our model-based price target is the fair value of $0.5270 (as of Sep 23, 2026) from 23 valuation models. Cautious scenario $0.2890, optimistic scenario $0.9180. It is a calculation from audited fundamentals, not an analyst target.
What is the USA Equities Corp stock forecast for 2026?
Our models put fair value at $0.5270, about +65% upside versus a price of $0.3200 (undervalued). Cautious scenario $0.2890, optimistic scenario $0.9180. The calculation is refreshed regularly with new filings.
What is the revenue of USA Equities Corp (USAQ)?
USA Equities Corp reported trailing-twelve-month revenue of about $2.8M (latest available figure, as of Sep 23, 2026).
What growth is priced into USA Equities Corp (USAQ)?
For today's price to be fair in a discounted-cash-flow model, USA Equities Corp would have to grow free cash flow by +12.5 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +84.9 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of USAQ use?
Our models discount USA Equities Corp at 8.5 %: a base by market capitalisation (nano), damped by beta 0.49, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For USA Equities Corp that is +12.5 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has USA Equities Corp (USAQ) delivered so far?
Over the past 5 years revenue at USA Equities Corp grew +84.9 % a year. The price currently implies +12.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of USA Equities Corp (USAQ) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into USA Equities Corp (+12.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of USA Equities Corp (USAQ)?
The free-cash-flow yield on the price is 3.70 %: that much free cash flow USA Equities Corp produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of USA Equities Corp (USAQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For USA Equities Corp it is $0.5270 per share (as of Sep 23, 2026), against a price of $0.3200. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is USA Equities Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, USAQ trades below its calculated fair value: price $0.3200, fair value $0.5270, a gap of about +65% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of USAQ?
No. The price is what the market pays today ($0.3200); the fair value is what the company's own numbers justify ($0.5270). For USA Equities Corp the two are $0.2070 per share apart. That gap is exactly why we show both numbers side by side.
How much is USA Equities Corp worth?
The market values USA Equities Corp at about $4.8M (market capitalisation, as of Sep 23, 2026). Per share that is $0.3200; our models calculate a fair value of $0.5270 per share.
What do the bullish and bearish scenarios say about USAQ?
Our models span a range for USA Equities Corp: cautious scenario $0.2890, base $0.5270, optimistic $0.9180 per share (as of Sep 23, 2026, price $0.3200). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of USAQ?
USA Equities Corp trades at a price-to-earnings ratio of 10.7 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.5270 is built from several models across several years. Other multiples: P/B 3.0, P/S 1.7, EV/EBITDA 35.3.
How solid is the balance sheet of USA Equities Corp (USAQ)?
Balance-sheet figures for USA Equities Corp (as of Sep 23, 2026): return on equity 93.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is USAQ from its 52-week high?
USA Equities Corp trades at $0.3200, about 65% below its 52-week high of $0.9200 and 300% above the low of $0.0800 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5270 is for.
Which stocks are comparable to USA Equities Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is USA Equities Corp stock attractive at the current price?
The data as of Sep 23, 2026: price $0.3200, calculated fair value $0.5270 (+65%), Quality Score 61/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of USAQ calculated?
We run USA Equities Corp through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5270, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. USA Equities Corp currently trades 65 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of USA Equities Corp (USAQ)?
The closing price on Sep 23, 2026 was $0.3200. Our model-based fair value is $0.5270, about +65% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with USA Equities Corp right now?
The model range is unusually wide ($0.2890 to $0.9180). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of USA Equities Corp
How large is the market capitalisation of USA Equities Corp (USAQ)?
The market capitalisation of USA Equities Corp is $4.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of USA Equities Corp (USAQ)?
The price-to-sales ratio of USA Equities Corp is 1.81 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of USA Equities Corp (USAQ)?
Earnings per share at USA Equities Corp are $0.0300 (price ÷ EPS = P/E 10.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of USA Equities Corp (USAQ)?
The net margin of USA Equities Corp is 17.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of USA Equities Corp (USAQ)?
The return on equity (ROE) of USA Equities Corp is 93.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of USA Equities Corp (USAQ)?
On an EBIT basis the return on assets of USA Equities Corp is −9.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of USA Equities Corp (USAQ)?
The operating margin of USA Equities Corp is −13.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at USA Equities Corp (USAQ)?
Revenue at USA Equities Corp is growing +12.9% versus a year earlier (3y avg +29.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at USA Equities Corp (USAQ)?
Earnings per share at USA Equities Corp are growing −35.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does USA Equities Corp (USAQ) carry?
The net debt of USA Equities Corp is $1.6M (fiscal year 2024, ≈ 8.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch USA Equities Corp in the live analysis
One click puts USA Equities Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026